Dexcom Officer Files Intent to Sell $227K in Company Stock

Sadie Stern, an Officer at Dexcom, Inc., has filed a Form 144 notice for a proposed sale of 2,565 shares of common stock with an aggregate market value of approximately $226,669. The intended sale date is around August 27, 2026. This transaction is being conducted under a Rule 10b5-1 trading plan, which was adopted on May 28, 2026. Such plans allow insiders to set up a predetermined schedule for selling stocks at a future date, providing an affirmative defense against accusations of trading on non-public information. The shares being sold were originally acquired as Restricted Stock. The value of the transaction is moderate for an executive, and its pre-planned nature suggests it is likely part of a personal financial management strategy rather than a reaction to recent company developments.